HRP20231035T1 - Monoklonska antitijela protiv krevetnih stjenica i postupci njihove proizvodnje i uporabe - Google Patents
Monoklonska antitijela protiv krevetnih stjenica i postupci njihove proizvodnje i uporabe Download PDFInfo
- Publication number
- HRP20231035T1 HRP20231035T1 HRP20231035TT HRP20231035T HRP20231035T1 HR P20231035 T1 HRP20231035 T1 HR P20231035T1 HR P20231035T T HRP20231035T T HR P20231035TT HR P20231035 T HRP20231035 T HR P20231035T HR P20231035 T1 HRP20231035 T1 HR P20231035T1
- Authority
- HR
- Croatia
- Prior art keywords
- conjugated
- monoclonal antibody
- antigen
- bed bugs
- binding fragment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 206010004194 Bed bug infestation Diseases 0.000 claims 20
- 241001414835 Cimicidae Species 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 20
- 241001327638 Cimex lectularius Species 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000002059 diagnostic imaging Methods 0.000 claims 1
- 238000005206 flow analysis Methods 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
- B22F1/0545—Dispersions or suspensions of nanosized particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/0004—Preparation of sols
- B01J13/0043—Preparation of sols containing elemental metal
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F2301/00—Metallic composition of the powder or its coating
- B22F2301/25—Noble metals, i.e. Ag Au, Ir, Os, Pd, Pt, Rh, Ru
- B22F2301/255—Silver or gold
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F2304/00—Physical aspects of the powder
- B22F2304/05—Submicron size particles
- B22F2304/054—Particle size between 1 and 100 nm
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F2304/00—Physical aspects of the powder
- B22F2304/05—Submicron size particles
- B22F2304/056—Particle size above 100 nm up to 300 nm
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (16)
1. Monoklonska antitijela protiv krevetnih stjenica proizvedena pomoću: (a) hibrida deponiranog u Američkoj zbirci tipova kultura (American Type Culture Collection – ATCC) pod pristupnim brojem PTA-122644 (BB2), ili njegovog fragmenta vezanja antigena ili (b) hibrida deponiranog u Američkoj zbirci tipova kultura – ATCC pristupnim brojem PTA-122645 (BB7) ili njegovog fragmenta vezanja antigena.
2. Konjugirano monoklonsko antitijelo ili konjugirani fragment vezanja antigena koji obuhvaća monoklonsko antitijelo protiv krevetnih stjenica ili fragment vezanja antigena sukladno patentnom zahtjevu 1 i sredstvo otkrivanja.
3. Konjugirano monoklonsko antitijelo ili konjugirani fragment vezanja antigena sukladno patentnom zahtjevu 2, pri čemu je sredstvo za detekciju enzimska oznaka, radio-oznaka, fluorofor, kromofor, sredstvo koji se koristi prilikom medicinskih snimanja, metal, metalni ion, koloidno zlato ili nanočestice zlata.
4. Konjugirano antitijelo ili konjugirani fragment vezanja antigena sukladno patentnim zahtjevima 2 ili 3, koje obuhvaća monoklonsko antitijelo protiv krevetnih stjenica proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura ATCC pod pristupnim brojem PTA-122644 (BB2) ili njegovog fragmenta vezanja antigena.
5. Konjugirano antitijelo ili konjugirani fragment vezanja antigena sukladno patentnim zahtjevima 2 ili 3, obuhvaća monoklonsko antitijelo protiv krevetnih stjenica proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura ATCC pod pristupnim brojem PTA-122645 (BB7) ili njegovog fragmenta vezanja antigena.
6. Pripravak koja obuhvaća monoklonsko antitijelo protiv krevetnih stjenica ili fragment vezanja antigena sukladno patentnom zahtjevu 1 konjugirano antitijelo ili konjugirani fragment vezanja antigena sukladno bilo kojem patentnom zahtjevu od 2 do 5 ili kombinaciju navedenih.
7. Pripravak sukladno patentnom zahtjevu 6 nadalje obuhvaća:
(a)(1) monoklonsko antitijelo protiv krevetnih stjenica sukladno patentnom zahtjevu 1 proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura ATCC pod pristupnim brojem PTA-122644 (BB2), i
(2) monoklonsko antitijelo protiv krevetnih stjenica sukladno patentnom zahtjevu 1 proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura (ATCC) pod pristupnim brojem PTA-122645 (BB7) ili konjugirano antitijelo sukladno patentnom zahtjevu 5; ili
(b)(1) monoklonsko antitijelo protiv krevetnih stjenica sukladno patentnom zahtjevu 1 proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura ATCC pod pristupnim brojem PTA-122645 (BB7), i
(2) konjugirano antitijelo sukladno patentnom zahtjevu 4.
8. Pribor koji obuhvaća monoklonsko antitijelo protiv krevetnih stjenica ili fragment vezanja antitijela sukladno patentnom zahtjevu 1, konjugirano antitijelo ili konjugirani fragment vezanja antigena sukladno bilo kojem od patentnih zahtjeva 2 do 5, pripravak sukladno patentnim zahtjevima 6 ili 7 ili kombinaciju navedenih.
9. Hibrid koji je sposoban za proizvodnju monoklonskog antitijela protiv krevetnih stjenica, pri čemu je hibrid deponiran u Američkoj zbirci tipova kultura (ATCC) pod pristupnim brojem PTA-122644 (BB2) ili pristupnim brojem PTA-122645 (BB7).
10. Izolirana stanica koja proizvodi monoklonsko antitijelo protiv krevetnih stjenica ili fragment vezanja antitijela sukladno patentnom zahtjevu 1.
11. Postupak proizvodnje monoklonskog antitijela protiv krevetnih stjenica ili fragment vezanja antigena sukladno patentnom zahtjevu 1, koje obuhvaća (a) kultiviranje stanice sukladno patentnom zahtjevu 10 i (b) izoliranje monoklonskog antitijela protiv krevetnih stjenica ili fragment vezanja antigena iz kultivirane stanice.
12. Postupak otkrivanja krevetnih stjenica koji obuhvaća dovođenje u kontakt uzorka koji obuhvaća antigen krevetne stjenice s monoklonskim antitijelom protiv krevetnih stjenica ili fragment vezanja antigena sukladno patentnom zahtjevu 1, konjugirano antitijelo ili konjugirani fragment vezanja antigena sukladno bilo kojem od patentnih zahtjeva 2 do 5, pripravak sukladno patentnim zahtjevima 6 ili 7 ili kombinaciju navedenih i otkrivanje vezanja antigena krevetnih stjenica na monoklonsko antitijelo protiv krevetnih stjenica ili fragment vezanja antigena, konjugiranog antitijela ili konjugiranog fragmenta vezanja antigena, pripravka ili njihove kombinacije, pri čemu otkrivanje poželjno obuhvaća izvođenje analize bočnog protoka.
13. Postupak sukladno patentnom zahtjevu 12, pri čemu je taj uzorak doveden u kontakt s monoklonskim antitijelom protiv krevetnih stjenica sukladno patentnom zahtjevu 1 i konjugiranim antitijelom sukladno bilo kojem od patentnih zahtjeva 2 do 5.
14. Postupak sukladno patentnom zahtjevu 13, pri čemu:
(a) monoklonsko antitijelo je protiv krevetnih stjenica je monoklonsko antitijelo protiv krevetnih stjenica sukladno patentnom zahtjevu 1 proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura (ATCC) pod pristupim brojem PTA-122644 (BB2) i konjugirano antitijelo je konjugirano antitijelo sukladno patentnom zahtjevu 5 ili
(b) monoklonsko antitijelo je protiv krevetnih stjenica monoklonsko antitijelo protiv krevetnih stjenica sukladno patentnom zahtjevu 1 proizvedeno pomoću hibrida deponiranog u Američkoj zbirci tipova kultura (ATCC) pod pristupnim brojem PTA-122645 (BB7) i konjugirano antitijelo je konjugirano antitijelo sukladno patentnom zahtjevu 4.
15. Postupak sukladno bilo kojem od patentnih zahtjeva 12 do 14, pri čemu taj postupak nadalje obuhvaća prikupljanje uzorka koji obuhvaća antigen krevetnih stjenica s uređajem za prikupljanje i izlučivanje antigena iz tog uzorka.
16. Postupak sukladno patentnom zahtjevu 15, pri čemu je uređaj za prikupljanje bris.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562244189P | 2015-10-21 | 2015-10-21 | |
EP16858386.2A EP3365367B1 (en) | 2015-10-21 | 2016-10-21 | Anti-bed bug monoclonal antibodies and methods of making and uses thereof |
PCT/US2016/058300 WO2017070603A1 (en) | 2015-10-21 | 2016-10-21 | Anti-bed bug monoclonal antibodies and methods of making and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231035T1 true HRP20231035T1 (hr) | 2023-12-22 |
Family
ID=58558142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231035TT HRP20231035T1 (hr) | 2015-10-21 | 2016-10-21 | Monoklonska antitijela protiv krevetnih stjenica i postupci njihove proizvodnje i uporabe |
Country Status (13)
Country | Link |
---|---|
US (1) | US10768172B2 (hr) |
EP (2) | EP3365367B1 (hr) |
AU (2) | AU2016342373B2 (hr) |
CA (1) | CA3041460A1 (hr) |
ES (1) | ES2953484T3 (hr) |
HR (1) | HRP20231035T1 (hr) |
HU (1) | HUE063822T2 (hr) |
MA (1) | MA45831B1 (hr) |
MD (1) | MD3365367T2 (hr) |
MX (2) | MX2018004986A (hr) |
PL (1) | PL3365367T3 (hr) |
RS (1) | RS64530B1 (hr) |
WO (1) | WO2017070603A1 (hr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3370515T (lt) | 2015-10-21 | 2022-05-10 | Redcoat Solutions, Inc. | Patalinių blakių aptikimo įrenginys |
CA3064284A1 (en) | 2017-05-22 | 2018-11-29 | Dow Agrosciences Llc | Selective detection of bed bugs |
AU2019384543A1 (en) | 2018-11-21 | 2021-06-10 | Ecolab Usa Inc. | Selective detection of bed bugs |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6319676B1 (en) | 1995-05-02 | 2001-11-20 | Carter Wallace, Inc. | Diagnostic detection device and method |
WO1999064863A1 (en) | 1998-06-12 | 1999-12-16 | New Horizons Diagnostics, Inc. | Colloidal colorimetric flow through and lateral flow assays utilizing soluble submicron particles |
JP2003511698A (ja) * | 1999-10-12 | 2003-03-25 | コンネクス・ゲゼルシャフト・ツーア・オプティミエルング・フォン・フォルシュング・ウント・エントヴィックルング・エムベーハー | 便中の酸耐性微生物の改良された検出方法 |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
US7220597B2 (en) | 2003-01-30 | 2007-05-22 | Zin Benedict L | Assay test device and method of making same |
US7214542B2 (en) | 2003-01-30 | 2007-05-08 | Michael Hutchinson | Method of processing assay test results |
US7482128B2 (en) | 2003-03-27 | 2009-01-27 | Heska Corporation | Anti-feline albumin antibodies |
KR20070072510A (ko) | 2004-08-30 | 2007-07-04 | 론자 바이올로직스 피엘씨 | 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피 |
US7727734B1 (en) * | 2005-07-27 | 2010-06-01 | Cytosignet, Inc. | Detection and measurement of blood-feeding activity |
US7591099B2 (en) | 2005-08-30 | 2009-09-22 | Ecolab Inc. | Bed bug monitor |
AU2007309475B2 (en) | 2006-10-23 | 2012-11-08 | Ecolab Usa Inc. | Bedbug detection, monitoring and control techniques |
AU2013200548B2 (en) | 2006-10-23 | 2015-06-18 | Ecolab Usa Inc. | Bedbug detection, monitoring and control techniques |
US20100273177A1 (en) | 2006-12-08 | 2010-10-28 | Piasio Roger N | Methods and Devices for Testing Saliva |
EP1933145B1 (en) | 2006-12-11 | 2011-09-28 | AraGen Biotechnology Co. Ltd. | Rapid immunochromatographic detection by amplification of the colloidal gold signal |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
KR20090130236A (ko) | 2007-03-13 | 2009-12-21 | 내셔날 쥬이쉬 헬스 | 항체의 제조 방법 |
JP2010525322A (ja) | 2007-04-20 | 2010-07-22 | クイデル コーポレイション | 統合乾燥剤付きの分析装置 |
US20090155921A1 (en) | 2007-12-12 | 2009-06-18 | Arbor Vita Corporation | Method and apparatus for reading test strips |
US8093364B2 (en) | 2008-01-18 | 2012-01-10 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
GB0809995D0 (en) | 2008-05-31 | 2008-07-09 | Spd Swiss Prec Diagnostics Gmb | Assay device |
GB0900669D0 (en) | 2009-01-16 | 2009-02-25 | Bed Bugs Ltd | Pest control |
US20100212213A1 (en) | 2009-02-25 | 2010-08-26 | Hope Iii Joe Harold | Detection device and method for monitoring bed bug infestation |
SG173862A1 (en) | 2009-03-13 | 2011-09-29 | Fmc Corp | Composition for attracting bed bugs |
US8577986B2 (en) | 2010-04-02 | 2013-11-05 | Microsoft Corporation | Mapping RDMA semantics to high speed storage |
US20110289824A1 (en) | 2010-05-28 | 2011-12-01 | Tai-Teh Wu | Compounds, methods, and devices for detecting and/or treating insect infestation |
FI20115285A0 (fi) | 2011-03-24 | 2011-03-24 | Reagena Ltd Oy | Menetelmä pikatestin suorittamiseksi |
US9458512B2 (en) | 2011-07-05 | 2016-10-04 | Ernest Colaizzi | Kit for the detection of bed bugs |
US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
US9140693B2 (en) | 2011-12-23 | 2015-09-22 | Abbott Point Of Care Inc. | Integrated test device for optical detection of microarrays |
CA2866084C (en) | 2012-02-29 | 2020-06-30 | Sri International | Ectoparasite detection |
US20130208114A1 (en) | 2013-01-25 | 2013-08-15 | Jody Arthur Balsam | Digital Bedbug Indicator: A bedbug insect peripheral electronic detection unit device |
GB2524307B (en) | 2014-03-20 | 2016-04-20 | Rentokil Initial Plc | Apparatus |
AU2015247338B2 (en) | 2014-04-17 | 2020-10-08 | Z-Integrated Digital Technologies, Inc. | Electronic test device data communication |
US20180244734A1 (en) * | 2015-08-31 | 2018-08-30 | Airmid Health Group Limited | Novel proteins and detection methods |
LT3370515T (lt) * | 2015-10-21 | 2022-05-10 | Redcoat Solutions, Inc. | Patalinių blakių aptikimo įrenginys |
-
2016
- 2016-10-21 MX MX2018004986A patent/MX2018004986A/es unknown
- 2016-10-21 PL PL16858386.2T patent/PL3365367T3/pl unknown
- 2016-10-21 RS RS20230760A patent/RS64530B1/sr unknown
- 2016-10-21 WO PCT/US2016/058300 patent/WO2017070603A1/en active Application Filing
- 2016-10-21 MA MA45831A patent/MA45831B1/fr unknown
- 2016-10-21 HU HUE16858386A patent/HUE063822T2/hu unknown
- 2016-10-21 AU AU2016342373A patent/AU2016342373B2/en active Active
- 2016-10-21 HR HRP20231035TT patent/HRP20231035T1/hr unknown
- 2016-10-21 ES ES16858386T patent/ES2953484T3/es active Active
- 2016-10-21 MD MDE20180844T patent/MD3365367T2/ro unknown
- 2016-10-21 EP EP16858386.2A patent/EP3365367B1/en active Active
- 2016-10-21 US US15/331,632 patent/US10768172B2/en active Active
- 2016-10-21 EP EP23177802.8A patent/EP4273235A3/en active Pending
- 2016-10-21 CA CA3041460A patent/CA3041460A1/en active Pending
-
2018
- 2018-04-23 MX MX2023009584A patent/MX2023009584A/es unknown
-
2023
- 2023-12-15 AU AU2023282327A patent/AU2023282327A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3041460A1 (en) | 2017-04-27 |
US20170137501A1 (en) | 2017-05-18 |
EP3365367A4 (en) | 2019-06-12 |
EP3365367B1 (en) | 2023-06-07 |
AU2016342373A1 (en) | 2018-06-07 |
EP4273235A3 (en) | 2024-01-17 |
EP3365367C0 (en) | 2023-06-07 |
MD3365367T2 (ro) | 2024-02-29 |
AU2016342373B2 (en) | 2023-09-21 |
ES2953484T3 (es) | 2023-11-13 |
MA45831A (fr) | 2019-06-12 |
US10768172B2 (en) | 2020-09-08 |
MX2023009584A (es) | 2023-08-23 |
PL3365367T3 (pl) | 2023-10-30 |
EP3365367A1 (en) | 2018-08-29 |
WO2017070603A9 (en) | 2018-05-17 |
MX2018004986A (es) | 2019-01-14 |
US20200363405A1 (en) | 2020-11-19 |
WO2017070603A1 (en) | 2017-04-27 |
AU2023282327A1 (en) | 2024-01-18 |
RS64530B1 (sr) | 2023-09-29 |
EP4273235A2 (en) | 2023-11-08 |
HUE063822T2 (hu) | 2024-02-28 |
MA45831B1 (fr) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
JP2017518366A5 (hr) | ||
RU2015103228A (ru) | Антитела против тау | |
NZ716369A (en) | Anti-ox40 antibodies and methods of using the same | |
AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
RU2014117161A (ru) | Композиции и способы испытаний на токсикогенность | |
EA200971124A1 (ru) | Множественный анализ образцов крови | |
HRP20231035T1 (hr) | Monoklonska antitijela protiv krevetnih stjenica i postupci njihove proizvodnje i uporabe | |
US8921055B2 (en) | Detecting cells secreting a protein of interest | |
AR098126A1 (es) | Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos | |
WO2008027942A3 (en) | Combination hepatitis c virus antigen and antibody detection method | |
JP2010526880A5 (hr) | ||
EA201590459A1 (ru) | Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение | |
PE20220004A1 (es) | Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh | |
RU2013142334A (ru) | КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ДЛЯ ОПРЕДЕЛЕНИЯ НЕ4а | |
RU2014146707A (ru) | Антитела против тофацитиниба и их применение для лекарственного мониторинга | |
MX2018008809A (es) | Anticuerpos monoclonales especificos para el antigeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por adv. | |
CN103880960B (zh) | 一种抗cd10分子的单克隆抗体及其应用 | |
EA201692071A1 (ru) | Иммуноанализ и антитела для обнаружения хромогранина а | |
CN103732627B (zh) | 包含抗-atic自身免疫抗体的肝癌诊断标记物以及包含其抗原的肝癌诊断用组合物 | |
FR2968767B1 (fr) | Procede et coffret pour le diagnostic in vitro du cancer de la prostate | |
WO2016069762A3 (en) | Subject anti-hcv antibody detection assays employing ns3 capture peptides | |
CN109061166B (zh) | 一种用于检测牛结核病的ELISpot检测试剂盒 | |
RU2009124225A (ru) | Мышиные моноклональные антитела, связывающиеся с антигеном f1 из yersinia pestis, способ их получения с использованием дрожжей, способ и набор для детекции yersinia pestis | |
MX2019003288A (es) | Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis. |